Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in Late Antibody-Mediated Renal Allograft Rejection
NCT05021484Phase 2Completed
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of felzartamab in antibody mediated rejection (AMR). Started Oct 2021; status: completed.
02
Drugs
felzartamab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT05021484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05021484.